Bookmark

Add to MyYahoo RSS

Eli Lilly News

News on Eli Lilly (Ticker: LLY) continually updated from thousands of sources around the net.

36 min ago | Reuters

Lilly's disappointing sales put focus on drug pipeline

Eli Lilly and Co reported lower-than-expected quarterly revenue on Thursday, hurt by disappointing sales of its cancer and diabetes drugs, and its shares fell more than 3 percent.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Diabetes, Health, Osteoporosis

4 hrs ago | Seeking Alpha

Eli Lilly's CEO Discusses Q1 2014 Results - Earnings Call Transcript

Ladies and gentlemen, thank you for standing by and welcome to the Eli Lilly First Quarter 2014 Earning Call.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Eli Lilly, Food and Drug Administration

5 hrs ago | Reuters

UPDATE 2-Zimmer to buy Biomet in $13.35 bln deal

Medical device maker Zimmer Holdings Inc said it would buy orthopedic products company Biomet Inc in a deal valued at about $13.35 billion to broaden its portfolio of products that treat bone and joint-related disorders.

Comment?

Related Topix: Medicine, Zimmer Holdings, Medical Equipment, Healthcare Industry, Biomet, Biotech

10 hrs ago | Pharmaceutical Online

Eli Lilly's Stomach Cancer Drug Approved By The FDA

Eli Lilly and Co. has announced that they will be putting their stomach cancer drug, Cyramza , on the market after it received federal marketing approval by the FDA this past Monday.

Comment?

Related Topix: Cancer, Health, Biotech, Healthcare Industry, Marketing

14 hrs ago | Pharmaceutical Processing

Eli Lilly First Quarter Profit Plunges

Eli Lilly's first-quarter earnings plunged 53 percent after the expiration of a key patent protecting its top-selling antidepressant cut into the drugmaker's revenue.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Osteoporosis, Health

18 hrs ago | National Public Radio

New Drug Sales Help Boost Novartis Q1 Profit

The company said Thursday that its net profit of nearly $2.97 billion, which was up from $2.42 billion in the same period last year, was helped by sales growth from some of its newest product launches, such as Gilenya for multiple sclerosis and Afinitor for cancer.

Comment?

Related Topix: Medicine, Biotech, Healthcare Industry

Wed Apr 23, 2014

AmericanBankingNews.com

Eli Lilly and Price Target Increased to $60.00 by Analysts at Jefferies Group

The firm currently has a "hold" rating on the stock. Jefferies Group's price objective suggests a potential upside of 0.74% from the company's current price.

Comment?

Related Topix: Alnara Pharmaceuticals, Biotech, Food, Medicine, Avid Radiopharmaceuticals, Agriculture, International Multifoods Corporation, Imclone Systems, Healthcare Industry, Eli Lilly

The Washington Post

Pharma Plan in Deal Frenzy Is to Be Best, First or Move On

That's the strategy the drug industry is following in a wave of deals where small companies are getting bigger and the big ones are getting smaller.

Comment?

Related Topix: Pfizer, Biotech, Medicine, Healthcare Industry, Cancer, Health, Noven Pharmaceuticals, Oncology

The Motley Fool

Why Pentair, Zions Bancorp, and Eli Lilly & Co. Are Today's 3 Worst Stocks

Are corporate profits at all-time highs? Not exactly. Are Americans getting full-time jobs like we've never seen before? That's a definitive no.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Banking, Zions Bancorporation, Financial Services, Financial Markets

The Motley Fool

Today's Health Care Stocks to Watch: Eli Lilly and Co, GlaxoSmithKline plc, Novartis AG, and Gilead

Let's take a look at today's top stories in biotech and health care. Keep an eye out for Eli Lilly ( Novartis brokers multibillion dollar deals with Eli Lilly and GlaxoSmithKline Fresh off the rumor that Pfizer was looking to buyout fellow pharma behemoth AstraZeneca , Novartis pushed through two major deals yesterday with Eli Lilly and ... (more)

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Financial Markets, Eli Lilly, Oncology, Influenza, Health, Food and Drug Administration

KDWN

Asia shares mixed on lackluster China data

Shares were mixed in Asia on Wednesday, as weak data from China sapped upward momentum from an overnight rally on a flurry of deals in the pharmaceutical sector.

Comment?

Related Topix: Biotech, Medicine, GlaxoSmithKline, Healthcare Industry, Financial Markets

Tue Apr 22, 2014

The Indianapolis Star

Animal medicines a winning deal for drug makers

Animal health is a $24 billion-a-year global business, with steady growth that is projected to nearly double in the next four years.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

ABC News

Investor Pressure Pushing Drugmaker M&A Deals

Drugmakers eager to satisfy shareholders by boosting profits and share prices are wheeling, dealing and in one case even making trades like a pro sports team looking to shake up its roster.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Forbes.com

With Big Pharma In Retreat, Ackman And Novartis Try A New Blueprint For Drug Companies

Yesterday in a move that returned attention to healthcare takeovers, Bill Ackman, CEO of the hedge fund Pershing Square Capital, announced a bold and unusual move by partnering with pharmaceutical company, Valeant Pharmaceuticals International plc's cancer-drug business for $14.5 billion and will sell most of its vaccine business to GSK for $7.1 ... (more)

Comment?

Related Topix: Biotech, Novartis, Medicine, Healthcare Industry, Forest Labs

Greenwich Citizen

FILE - The Oct. 19, 2012 file photo shows a Novartis employee in a...

The Jan 11, 2011 file photo shows tram wires outside the Novartis headquarters in Basel, Switzerland.

Comment?

Related Topix: Biotech, Novartis, Noven Pharmaceuticals, Healthcare Industry

The Washington Post

Novartis Buys Glaxo Cancer Unit, Sells Animal Drugs to Lilly

Novartis AG agreed to buy GlaxoSmithKline Plc's cancer drugs for as much as $16 billion while selling most of the company's vaccines division to Glaxo for $7.1 billion and its animal-health unit to Eli Lilly & Co.

Comment?

Related Topix: Medicine, Cancer, Biotech, Noven Pharmaceuticals, Healthcare Industry, Business News

Mon Apr 21, 2014

Reuters

UPDATE 1-Eli Lilly to buy Novartis' animal health unit for $5.4 bln

Eli Lilly and Co said on Tuesday it will buy Swiss drugmaker Novartis AG's animal health business for $5.4 billion in cash to strengthen and diversify its Elanco unit.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Eli Lilly

Reuters

Eli Lilly to buy Novartis' animal health business for $5.4 bln

Eli Lilly and Co said on Tuesday it will buy Novartis AG's animal health business for $5.4 billion in cash to strengthen and diversify its Elanco unit.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Eli Lilly

Sys-Con Media

Lilly's CYRAMZAa (ramucirumab) Becomes First FDA-Approved...

With this approval, CYRAMZA becomes the first FDA-approved treatment for patients in this setting.

Comment?

Related Topix: Healthcare Law, Law, Food and Drug Administration, Biotech, Medicine, Healthcare Industry, Pancreatic Cancer, Health, Oncology

Reuters

U.S. FDA approves Eli Lilly drug for stomach cancer

U.S. health regulators on Monday approved an Eli Lilly and Co drug to treat advanced stomach cancer and a form of cancer in the area where the esophagus joins the stomach.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Oncology

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••
•••